Login / Signup

Next Steps for Immunotherapy in Glioblastoma.

Toni Q CaoDerek A WainwrightCatalina Lee-ChangJason M MiskaAdam M SonabendAmy B HeimbergerRimas V Lukas
Published in: Cancers (2022)
Outcomes for glioblastoma (GBM) patients undergoing standard of care treatment remain poor. Here we discuss the portfolio of previously investigated immunotherapies for glioblastoma, including vaccine therapy and checkpoint inhibitors, as well as novel emerging therapeutic approaches. In addition, we explore the factors that potentially influence response to immunotherapy, which should be considered in future research aimed at improving immunotherapy efficacy.
Keyphrases
  • patients undergoing
  • healthcare
  • dna damage
  • palliative care
  • current status
  • pain management
  • adipose tissue
  • stem cells
  • metabolic syndrome
  • mass spectrometry
  • oxidative stress
  • chronic pain
  • combination therapy